Patients
Our patients
are at the core
of what we do.
We’d like to express our appreciation for the patients who have previously participated or are currently enrolled in our clinical trials. Your contributions will help others as a result of the knowledge gained from your participation.
Veverimer Phase 3 Revive Study
Veverimer is an oral, non-absorbed hydrochloric acid binder in Phase 3 development for the treatment of patients with chronic kidney disease and metabolic acidosis.
Veverimer has received Orphan Drug Designation from the US Food and Drug Administration for the treatment of anti-glomerular basement membrane disease (anti-GBM), an ultra-rare life-threatening condition characterized by acute renal failure associated with the presence of auto-immune antibodies with affinity for the glomerular basement membrane.
While our current development focus for veverimer is on the Phase 3 REVIVE trial, we may explore this and other orphan indications in the future.
Advocacy Research Partnerships
